UBS Group Has Lowered Expectations for CVS Health (NYSE:CVS) Stock Price

CVS Health (NYSE:CVS) had its target price reduced by stock analysts at UBS Group from $118.00 to $107.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the pharmacy operator’s stock. UBS Group‘s price target points to a potential upside of 31.74% from the company’s previous close.

A number of other brokerages have also issued reports on CVS. Piper Sandler set a $112.00 price target on CVS Health in a research note on Wednesday, September 9th. Evercore reaffirmed an “outperform” rating on shares of CVS Health in a research report on Wednesday. Cantor Fitzgerald reiterated a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. TD Cowen reiterated a “buy” rating on shares of CVS Health in a research report on Wednesday. Finally, Barclays lowered their target price on shares of CVS Health from $108.00 to $107.00 and set an “overweight” rating for the company in a research note on Thursday. Twenty-two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $108.96.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $81.22 on Thursday. The company has a current ratio of 0.85, a quick ratio of 0.66 and a debt-to-equity ratio of 0.71. CVS Health has a 12 month low of $69.51 and a 12 month high of $110.68. The company has a market capitalization of $103.88 billion, a price-to-earnings ratio of 9.46, a PEG ratio of 0.73 and a beta of 0.58. The firm’s 50-day moving average is $90.56 and its 200 day moving average is $88.87.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.65 by $0.44. CVS Health had a net margin of 2.62% and a return on equity of 13.65%. The business had revenue of $108.40 billion during the quarter, compared to the consensus estimate of $104.72 billion. During the same quarter last year, the firm earned $1.60 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Research analysts predict that CVS Health will post 8.20 EPS for the current year.

Institutional Investors Weigh In On CVS Health

Hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of CVS Health in the 2nd quarter worth $12,747,462,000. State Street Corp boosted its position in shares of CVS Health by 26.3% during the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock valued at $7,751,205,000 after acquiring an additional 15,604,883 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of CVS Health by 49.8% during the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after acquiring an additional 11,233,381 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of CVS Health by 148.0% in the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after purchasing an additional 13,836,701 shares during the period. Finally, Pzena Investment Management LLC purchased a new stake in shares of CVS Health in the second quarter valued at about $1,217,558,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported third-quarter adjusted EPS of $2.09, beating the $1.65 consensus, while revenue rose 5.4% to $108.4 billion. Management also raised its 2026 earnings outlook, supporting the view that operating performance is improving. CVS Health third-quarter results
• Neutral Sentiment: Leerink Partners and Barclays lowered their price targets but kept Outperform and Overweight ratings, respectively—signaling continued confidence in potential upside while reflecting greater uncertainty. Leerink Partners price target
• Negative Sentiment: CVS plans to separate its retail pharmacy business from its insurance and pharmacy-benefit operations, creating two public companies by 2028. Investors have reacted negatively to the surprise announcement and lack of detail on separation costs, debt allocation, dividends, and the businesses’ standalone finances. CVS breakup announcement
• Negative Sentiment: The split reverses CVS’s strategy of combining pharmacies, Aetna, and Caremark, raising questions about whether the breakup will improve results or simply add execution costs and uncertainty. Commentary also cautions that separating the businesses may not make prescriptions more affordable. Analysis of CVS’s merger strategy
• Negative Sentiment: AM Best placed ratings for Aetna insurance subsidiaries under review with developing implications, adding to uncertainty as the corporate structure changes. AM Best ratings review

CVS Health Company Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.